Nurix Therapeutics Files 8-K on Shareholder Votes and Financials
Ticker: NRIX · Form: 8-K · Filed: May 21, 2024 · CIK: 1549595
Sentiment: neutral
Topics: corporate-governance, financial-reporting
Related Tickers: NRIX
TL;DR
Nurix filed an 8-K for shareholder votes & financials. All good.
AI Summary
Nurix Therapeutics, Inc. filed an 8-K on May 20, 2024, to report on the submission of matters to a vote of security holders and financial statements. The filing details the company's corporate structure and its principal executive offices located at 1700 Owens Street, Suite 205, San Francisco, CA 94158.
Why It Matters
This filing provides an update on corporate governance and financial reporting for Nurix Therapeutics, Inc., which is relevant for investors tracking the company's operational and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate matters and does not indicate any unusual risks.
Key Players & Entities
- Nurix Therapeutics, Inc. (company) — Registrant
- May 20, 2024 (date) — Date of Earliest Event Reported
- 1700 Owens Street, Suite 205 (location) — Principal Executive Offices Address
- San Francisco, California 94158 (location) — Principal Executive Offices City, State, Zip
- 001-39398 (document_id) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing for Nurix Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on the submission of matters to a vote of security holders and to provide financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 20, 2024.
What is the exact address of Nurix Therapeutics, Inc.'s principal executive offices?
The address of Nurix Therapeutics, Inc.'s principal executive offices is 1700 Owens Street, Suite 205, San Francisco, California 94158.
What is the SEC file number for Nurix Therapeutics, Inc.?
The SEC file number for Nurix Therapeutics, Inc. is 001-39398.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 847 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-05-21 07:06:54
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share NRIX Nasdaq Global
Filing Documents
- nrix-20240520.htm (8-K) — 41KB
- 0001549595-24-000073.txt ( ) — 166KB
- nrix-20240520.xsd (EX-101.SCH) — 2KB
- nrix-20240520_lab.xml (EX-101.LAB) — 22KB
- nrix-20240520_pre.xml (EX-101.PRE) — 13KB
- nrix-20240520_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 20, 2024, Nurix Therapeutics, Inc. (the " Company ") held its virtual 2024 Annual Meeting of Stockholders exclusively online via live webcast (the " Annual Meeting "). At the Annual Meeting, the Company's stockholders voted on three proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 27, 2024 (the " Proxy Statement "). There were 39,059,365 shares of common stock present at the Annual Meeting in person or by proxy, which represented approximately 79.46% of the voting power of the shares of common stock entitled to vote at the Annual Meeting and constituted a quorum for the transaction of business. Holders of the Company's common stock were entitled to one vote for each share held as of the close of business on March 21, 2024. The stockholders of the Company voted on the following proposals at the Annual Meeting: 1. To elect two Class I directors, each of whom is currently serving on the Company's Board of Directors (the " Board "), each to serve a three-year term expiring at the Company's 2027 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal. 2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2024. 3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. The final voting results for each of these proposals are detailed below. Proposal 1. Election of Directors Nominee Votes For Votes Withheld Broker Non-Votes Julia P. Gregory 29,941,782 4,521,729 4,595,854 David L. Lacey, M.D. 27,120,017 7,343,494 4,595,854 Each of the two nominees for director was elected to serve until the Company's 202
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith and this list is intended to constitute the exhibit index: Exhibit No. Exhibit Title or Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: May 21, 2024 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer 4